LIXTE Biotechnology Holdings has expanded its cancer treatment pipeline through the acquisition of Liora Technologies, a company pioneering proton therapy systems for treating various cancers. The acquisition includes Liora's proprietary LiGHT System, a Linac for Image Guided Hadron Therapy that offers significant advantages over existing proton therapy technologies.
Professor Steve Myers, former Director of Accelerators and Technology at CERN, explained the system's capabilities. "The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors," Myers said. "In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve."
This development matters because proton therapy represents a growing segment of cancer treatment that offers more precise targeting of tumors while minimizing damage to surrounding healthy tissue. Current proton therapy systems require substantial infrastructure investment and often limit patient access due to high costs and limited treatment capacity. The LiGHT System's potential to reduce both installation costs and treatment sessions could make this advanced therapy more accessible to patients worldwide.
The implications for cancer treatment are substantial. If the LiGHT System delivers on its promise, more cancer centers could afford to offer proton therapy, potentially expanding treatment options for patients with tumors in sensitive locations where traditional radiation therapy poses significant risks. The system's ability to deliver high dose rates to deep-seated tumors could also improve outcomes for challenging cancer cases.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development. The company has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE's approach represents a new treatment paradigm in cancer biology called activation lethality, which is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer. The acquisition of Liora Technologies positions LIXTE to address cancer treatment through both pharmaceutical and advanced radiation therapy approaches.
For the cancer treatment industry, this acquisition signals continued innovation in combining different therapeutic modalities. The integration of advanced radiation technology with novel pharmaceutical approaches could lead to more comprehensive treatment strategies. Patients may benefit from more effective, less invasive treatment options that reduce both the physical burden of treatment and the financial strain on healthcare systems.
As with all medical innovations, the LiGHT System will require clinical validation and regulatory approval before becoming widely available. However, the potential to make proton therapy more accessible represents an important step forward in cancer care. The full terms of use and disclaimers for this information can be found at http://IBN.fm/Disclaimer.
